AARTIDRUGS vs BLISSGVS: Stock Comparison

AARTI DRUGS vs BLISSGVSUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

BLISSGVS is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E, a higher ROE and a higher dividend yield, while BLISSGVS shows faster revenue growth, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 8; BLISSGVS leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSBLISSGVS

Valuation lens

What price are you paying?

Market CapContext only
₹3,973 Cr
₹7,092 Cr
P/E RatioAARTIDRUGS has the lower reading
20x
51.05x
P/B RatioAARTIDRUGS has the lower reading
2.47x
5.83x
EPSAARTIDRUGS has the higher reading
₹5.57
₹3.64
Book ValueContext only
₹169.74
₹116.14
Dividend YieldAARTIDRUGS has the higher reading
0.46%
0.22%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
BLISSGVS is the larger company
₹7,092 Cr vs ₹3,973 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
20x vs 51.05x
P/B Ratio
AARTIDRUGS has a lower P/B
2.47x vs 5.83x
EPS
AARTIDRUGS has higher earnings per share
₹5.57 vs ₹3.64
Dividend Yield
AARTIDRUGS has a higher dividend yield
0.46% vs 0.22%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs 6.4%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs -12%
Qtr Sales Growth
AARTIDRUGS has stronger quarterly sales growth
-10.72% vs -22.41%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSBLISSGVS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSBLISSGVS
Live Price₹431.65₹527.1
Day Change1.36%0.68%
Volume2.5 L3.93 L
52-Week High₹534.55₹553
52-Week Low₹318.95₹118
Distance from 52W High-19.25%-4.68%

Valuation

MetricAARTIDRUGSBLISSGVS
Market Cap₹3,973 Cr₹7,092 Cr
P/E Ratio20x51.05x
P/B Ratio2.47x5.83x
EPS₹5.57₹3.64
Book Value₹169.74₹116.14
Dividend Yield0.46%0.22%

Growth

MetricAARTIDRUGSBLISSGVS
Revenue Growth (TTM YoY)6.4%29.8%
EPS Growth (TTM YoY)-12%124.7%
Qtr Sales Growth-10.72%-22.41%
Qtr Profit Growth1.44%-24.83%

Profitability & Leverage

MetricAARTIDRUGSBLISSGVS
ROE12.05%8.39%
ROCE10.64%9.11%
Net Margin7.6%13.93%
Operating Margin9.19%19.81%
Debt to Equity0.3x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIDRUGSBLISSGVS
Promoter Holding54.43% 0.6 pp35.01% 0.35 pp
FII Holding1.52% 0.06 pp8.07% 2.38 pp
DII Holding10.29% 0.07 pp9.47% 4.43 pp
Public Holding33.75% 0.57 pp47.45% 1.7 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and BLISSGVS.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.